Affimed Highlights the Potential of its Innate Cell Engager AFM24 as EGFR-targeting Therapy for Solid Tumors as Monotherapy a...
April 12 2021 - 6:30AM
- AFM24 induces strong tumor cell killing independent of KRAS
mutations
- AFM24, in combination with adoptive NK cells, leads to
dose-dependent tumor regression
Heidelberg, Germany, April 12, 2021 – Affimed
N.V. (Nasdaq: AFMD), a clinical-stage immuno-oncology company
committed to giving patients back their innate ability to fight
cancer, announces pre-clinical data on its Innate Cell Engager
(ICE®) AFM24 as monotherapy and in combination with adoptively
transferred NK cells at the American Association for Cancer
Research (AACR) Virtual Annual Meeting I.
AFM24, an EGFR/CD16A-binding ICE®, mediates antibody-dependent
cellular cytotoxicity (ADCC) and antibody-dependent cellular
phagocytosis (ADCP) and has the potential to overcome toxicity and
resistance hurdles associated with current EGFR signaling
inhibitors through its differentiated mechanism of action. AFM24
induces NK cell-mediated ADCC against EGFR-expressing tumor cells
even in the presence of competing IgG and can induce potent cell
killing in tumors independent of KRAS mutations.
In addition, data from a xenograft mouse model demonstrate that
AFM24 in combination with adoptively transferred NK cells results
in dose-dependent tumor regression.
“AFM24’s novel mechanism of action is independent of EGFR
signaling and has the potential to change the treatment paradigm
for EGFR-expressing solid tumors,” said Dr. Arndt Schottelius,
Affimed’s Chief Scientific Officer. “Demonstrating that AFM24, in
combination with NK cells, shows tumor regression in vivo is an
important pre-clinical proof of concept. Combination therapies with
NK cells could broaden the potential AFM24 opportunities to treat a
range of EGFR-expressing malignancies.”
Affimed is currently evaluating AFM24 as monotherapy for
patients with advanced EGFR-expressing solid malignancies whose
disease has progressed after treatment with previous anticancer
therapies. AFM24-101 is a first-in-human Phase 1/2a open-label,
non-randomized, multi-center, multiple ascending dose escalation
and expansion study. Additional information about the trial may be
found at www.clinicaltrials.gov, using the identifier
NCT04259450.
In March 2020, the U.S. Food and Drug Administration (FDA)
cleared an investigational new drug application (IND) for a Phase
1/2a study investigating the combination of AFM24 with SNK-01, an
autologous NK cell product of NKGen Biotech (formerly known as
NKMax America), in cancer patients with EGFR-expressing tumors.
In February 2020, Affimed announced a clinical collaboration
with Roche to explore the combination of AFM24 with Roche’s PD-L1
checkpoint inhibitor atezolizumab (Tecentriq®).
About Affimed N.V.
Affimed (Nasdaq: AFMD) is a clinical-stage immuno-oncology
company committed to give patients back their innate ability to
fight cancer by actualizing the untapped potential of the innate
immune system. The company’s proprietary ROCK® platform enables a
tumor-targeted approach to recognize and kill a range of
hematologic and solid tumors, enabling a broad pipeline of
wholly-owned and partnered single agent and combination therapy
programs. The ROCK® platform predictably generates customized
innate cell engager (ICE®) molecules, which use patients’ immune
cells to destroy tumor cells. This innovative approach enabled
Affimed to become the first company with a clinical-stage ICE®.
Headquartered in Heidelberg, Germany, with offices in New York, NY,
Affimed is led by an experienced team of biotechnology and
pharmaceutical leaders united by a bold vision to stop cancer from
ever derailing patients’ lives. For more about the company’s
people, pipeline and partners, please visit: www.affimed.com.
Forward-Looking Statements
This press release contains forward-looking statements. All
statements other than statements of historical fact are
forward-looking statements, which are often indicated by terms such
as “anticipate,” “believe,” “could,” “estimate,” “expect,” “goal,”
“intend,” “look forward to,” “may,” “plan,” “potential,” “predict,”
“project,” “should,” “will,” “would” and similar expressions.
Forward-looking statements appear in a number of places throughout
this release and include statements regarding our intentions,
beliefs, projections, outlook, analyses and current expectations
concerning, among other things, the potential of AFM13, AFM24, and
our other product candidates, the value of our ROCK® platform, our
ongoing and planned preclinical development and clinical trials,
our collaborations and development of our products in combination
with other therapies, the timing of and our ability to make
regulatory filings and obtain and maintain regulatory approvals for
our product candidates, our intellectual property position, our
collaboration activities, our ability to develop commercial
functions, clinical trial data, our results of operations, cash
needs, financial condition, liquidity, prospects, future
transactions, growth and strategies, the industry in which we
operate, the trends that may affect the industry or us, impacts of
the COVID-19 pandemic, the benefits to Affimed of orphan drug
designation and the risks, uncertainties and other factors
described under the heading “Risk Factors” in Affimed’s filings
with the SEC. Given these risks, uncertainties, and other factors,
you should not place undue reliance on these forward-looking
statements, and we assume no obligation to update these
forward-looking statements, even if new information becomes
available in the future.
Investor Relations Contact
Alexander FudukidisDirector, Investor RelationsE-Mail:
a.fudukidis@affimed.comTel.: +1 (917) 436-8102
Media Contact
Mary Beth Sandin Vice President, Marketing and
CommunicationsE-Mail: m.sandin@affimed.com
Affimed NV (NASDAQ:AFMD)
Historical Stock Chart
From Mar 2024 to Apr 2024
Affimed NV (NASDAQ:AFMD)
Historical Stock Chart
From Apr 2023 to Apr 2024